95 related articles for article (PubMed ID: 7529517)
21. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
Frost P; Caliliw R; Belldegrun A; Bonavida B
Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
[TBL] [Abstract][Full Text] [Related]
22. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells.
Deaglio S; Canella D; Baj G; Arnulfo A; Waxman S; Malavasi F
Leuk Res; 2001 Mar; 25(3):227-35. PubMed ID: 11226519
[TBL] [Abstract][Full Text] [Related]
23. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
Mizutani Y; Bonavida B; Nio Y; Yoshida O
Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609
[TBL] [Abstract][Full Text] [Related]
24. Expression of adhesion molecules (ICAM-1, LFA-3) on human epithelial cells (A549) after respiratory syncytial virus infection.
Arnold R; Werchau H; König W
Int Arch Allergy Immunol; 1995; 107(1-3):392-3. PubMed ID: 7542091
[No Abstract] [Full Text] [Related]
25. From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas.
Chaperot L; Jacob MC; Molens JP; Manches O; Bensa JC; Plumas J
Leuk Lymphoma; 2000 Jul; 38(3-4):247-63. PubMed ID: 10830732
[TBL] [Abstract][Full Text] [Related]
26. Immunosuppressive effect of shedding intercellular adhesion molecule 1 antigen on cell-mediated cytotoxicity against tumor cells.
Koyama S
Jpn J Cancer Res; 1994 Feb; 85(2):131-4. PubMed ID: 7908284
[TBL] [Abstract][Full Text] [Related]
27. Cancer cell cycle and adoptive immunotherapy using lymphokine-activated killer cells.
Ejiri Y; Ohara M; Suzuki T; Kasukawa R
Fukushima J Med Sci; 1997 Dec; 43(2):61-73. PubMed ID: 9640842
[TBL] [Abstract][Full Text] [Related]
28. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
29. Membrane-associated lymphotoxin-expressing lymphokine-activated killer cells up-regulate intercellular adhesion molecule-1 expression on target tumor cells in vitro.
Kimura K; Abe Y; Horiuchi A; Miyake M; Kimura S
Cell Immunol; 1995 Aug; 164(1):119-25. PubMed ID: 7634343
[TBL] [Abstract][Full Text] [Related]
30. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells.
Matsuzaki I; Suzuki H; Kitamura M; Minamiya Y; Kawai H; Ogawa J
Oncology; 2000 Nov; 59(4):336-43. PubMed ID: 11096347
[TBL] [Abstract][Full Text] [Related]
32. GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1.
Bendall LJ; Kortlepel K; Gottlieb DJ
Leukemia; 1995 Apr; 9(4):677-84. PubMed ID: 7723403
[TBL] [Abstract][Full Text] [Related]
33. Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: participation of ICAM-1 induction on target cells.
Naganuma H; Kiessling R; Patarroyo M; Hansson M; Handgretinger R; Grönberg A
Int J Cancer; 1991 Feb; 47(4):527-32. PubMed ID: 1671670
[TBL] [Abstract][Full Text] [Related]
34. The influence of cryopreservation on activity and surface markers of lymphokine-activated killer cells.
Letellier C; Rameliarison L; Fizet D; Ferrer AM; Vezon G
Vox Sang; 1991; 61(2):90-5. PubMed ID: 1763504
[TBL] [Abstract][Full Text] [Related]
35. Purification and characterisation of soluble intercellular adhesion molecule-1 and its effect on cell-mediated cytolysis of bladder tumour cells.
Young DG; Jackson AM; James K
Biochem Soc Trans; 1997 May; 25(2):365S. PubMed ID: 9191410
[No Abstract] [Full Text] [Related]
36. Expression of adhesion molecules CD11/CD18 (Leu-CAMs, beta 2-integrins), CD54 (ICAM-1) and CD58 (LFA-3) in B-chronic lymphocytic leukemia.
Kimby E; Rincón J; Patarroyo M; Mellstedt H
Leuk Lymphoma; 1994 Apr; 13(3-4):297-306. PubMed ID: 7519509
[TBL] [Abstract][Full Text] [Related]
37. A lymphokine-activated killer (LAK)-resistant cell line, and low expression of adhesion molecules LFA-3 and VCAM-1 on its cell surface.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(5):263-9. PubMed ID: 9802061
[TBL] [Abstract][Full Text] [Related]
38. Human T-cell leukemia virus type 1 (HTLV-1) p12I down-modulates ICAM-1 and -2 and reduces adherence of natural killer cells, thereby protecting HTLV-1-infected primary CD4+ T cells from autologous natural killer cell-mediated cytotoxicity despite the reduction of major histocompatibility complex class I molecules on infected cells.
Banerjee P; Feuer G; Barker E
J Virol; 2007 Sep; 81(18):9707-17. PubMed ID: 17609265
[TBL] [Abstract][Full Text] [Related]
39. Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-alpha.
Yoshida J; Takaoka T; Mizuno M; Momota H; Okada H
J Surg Oncol; 1996 Jul; 62(3):177-82. PubMed ID: 8667624
[TBL] [Abstract][Full Text] [Related]
40. Differential involvement of CD40, CD80, and major histocompatibility complex class I molecules in cytotoxicity induction and interferon-gamma production by human natural killer effectors.
Terrazzano G; Zanzi D; Palomba C; Carbone E; Grimaldi S; Pisanti S; Fontana S; Zappacosta S; Ruggiero G
J Leukoc Biol; 2002 Aug; 72(2):305-11. PubMed ID: 12149421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
